News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
May 07, 2019
Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in ChinaAug 01, 2018
Clover Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in ChinaJun 18, 2018
Clover Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant AscitesJan 23, 2018
Clover selects GE's FlexFactory biomanufacturing platform for its new production facility in ChinaDec 22, 2017
Clover Receives CFDA Approval to Initiate Clinical Trials in China with Etanercept Biosimilar Candidate SCB-808Dec 14, 2017
Clover Completes RMB 62.8 Million Series A FinancingOct 15, 2016
Clover Scientists' Discovery Featured on the Cover of The Journal of ImmunologyFeb 19, 2016
Clover initiates GLP studies on SCB-313 (Trail-Trimer) at National Shanghai Center for New Drug Safety Evaluation and Research.Nov 13, 2015
Clover filed IND with CFDA for SCB-808, a ready-for-injection biosimilar of blockbuster anti-TNF biologic, Enbrel (etanercept)Oct 23, 2015
Clover initiated gp120-Trimer (SCB-703) AIDS vaccine study
